Neuromyelitis Optica Spectrum Disorder — Research Summary
Printed from RareWays (rareways.com.au) on 27 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Statement of Retraction: The role of autophagy-related proteins in the pathogenesis of neuromyelitis optica spectrum disorders.
— Bioengineered (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42165560/
- 2.
Associations between perfluoroalkyl substances and multiple sclerosis in U.S. cohorts compared with NMOSD, MOGAD, and healthy controls.
Briggs Farren B S et al. — Environmental research (15 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42142568/
- 3.
Chimeric antigen receptor T-cell therapy in neurological disorders: Emerging applications, evidence, and challenges.
Luo Jin Jun et al. — Journal of the neurological sciences (15 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42134213/
- 4.
Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis.
Zammar Khaled et al. — Journal of neuroimmunology (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42105562/
- 5.
Dynamic characterization of pathological and functional deterioration in a mouse model of optic neuritis related to neuromyelitis optica spectrum disorder.
Yang Xiayin et al. — Neural regeneration research (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42057707/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Recruiting — Alexion Pharmaceuticals, Inc.
https://clinicaltrials.gov/study/NCT06312644
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Neuromyelitis Optica Spectrum Disorder
Neuromyelitis Optica Spectrum Disorder is a rare autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord. It is frequently misdiagnosed as Multiple Sclerosis. The majority of cases involve antibodies against aquaporin-4 (AQP4) water channels. Timely diagnosis is critical as some MS treatments can worsen NMOSD.
Most Recent Research
Common Questions
What is Neuromyelitis Optica Spectrum Disorder?
Neuromyelitis Optica Spectrum Disorder is a rare autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord. It is frequently misdiagnosed as Multiple Sclerosis. The majority of cases involve antibodies against aquaporin-4 (AQP4) water channels. Timely diagnosis is critical as some MS treatments can worsen NMOSD.
How many clinical trials are available for Neuromyelitis Optica Spectrum Disorder?
RareWays currently indexes 133 clinical trials for Neuromyelitis Optica Spectrum Disorder, of which 44 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Neuromyelitis Optica Spectrum Disorder come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Neuromyelitis Optica Spectrum Disorder.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.